Critical Survey: Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ:ATOS) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Profitability

This table compares Atossa Genetics and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-49.42%	-44.76%
Hyperfine	-378.17%	-97.95%	-75.87%

Valuation & Earnings

This table compares Atossa Genetics and Hyperfine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($3.60)	-1.42
Hyperfine	$12.89 million	9.57	-$40.72 million	($0.52)	-2.44

Atossa Genetics has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 9.5% of Atossa Genetics shares are held by company insiders. Comparatively, 31.0% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Atossa Genetics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Atossa Genetics and Hyperfine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	2	1	2.40
Hyperfine	1	1	2	0	2.25

Atossa Genetics presently has a consensus price target of $95.00, suggesting a potential upside of 1,759.10%. Hyperfine has a consensus price target of $1.28, suggesting a potential upside of 1.05%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, research analysts clearly believe Atossa Genetics is more favorable than Hyperfine.

Summary

Atossa Genetics beats Hyperfine on 9 of the 13 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.